Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

600276 Jiangsu Hengrui Pharmaceuticals Co.,Ltd.

Closed 04-09 15:00:00

56.96

-0.49

-0.85%

High57.97	Low56.71	Vol48.08M
Open56.92	D1 Closing57.45	Amplitude2.19%
Mkt Cap378.04B	Tradable Cap363.35B	Total Shares6.64B
T/O2.75B	T/O Rate0.75%	Tradable Shares6.38B
P/B6.17	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.","latestPrice":56.96,"timestamp":1775718000000,"preClose":57.45,"halted":0,"volume":48075474,"delay":0,"changeRate":-0.0085,"floatShares":6379000000,"shares":6637000000,"eps":1.3689,"marketStatus":"Closed","change":-0.49,"latestTime":"04-09 15:00:00","open":56.92,"high":57.97,"low":56.71,"amount":2750000000,"amplitude":0.0219,"askPrice":56.97,"askSize":41,"bidPrice":56.96,"bidSize":209,"shortable":0,"etf":0,"ttmEps":1.3689,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1775784600000},"marketStatusCode":5,"adr":0,"adjPreClose":57.45,"symbolType":"stock","openAndCloseTimeList":[[1775698200000,1775705400000],[1775710800000,1775718000000]],"highLimit":63.2,"lowLimit":51.71,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":6.17,"roa":"--","peRate":41.610052,"roe":"14.26%","epsLYR":1.19,"committee":0.345622,"marketValue":378055000000,"turnoverRate":0.0075,"status":1,"hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"HENGRUI PHARMA","latestPrice":66.65,"timestamp":1775722093003,"preClose":66.65,"halted":0,"volume":2439935,"delay":0,"premium":"+2.15"},"floatMarketCap":363348000000},"requestUrl":"/m/hq/s/600276/wiki","defaultTab":"wiki","newsList":[{"id":"2626900022","title":"Morgan Stanley's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals  Increases to 9.85% on Apr 1 From 1.17% - HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2626900022","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626900022?lang=en_us&edition=fundamental","pubTime":"2026-04-09 17:30","pubTimestamp":1775727043,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nFWN40S0K4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2148510915.USD","LU1997245177.USD","LU1820825898.SGD","LU2289578879.USD","LU2495084118.USD","BK0239","BK0060","BK0183","LU1997244956.HKD","LU1328615791.USD","LU1997245094.SGD","600276","LU1023057109.AUD","LU0359201612.USD","BK1191","01276","LU1655091616.SGD","LU1781817850.SGD","LU1969619763.USD","LU2580892862.HKD","LU0405327148.USD","LU2097828631.EUR","BK0012","LU0405327494.USD","LU0359202008.SGD","LU1255011170.USD","BK0028","LU2097828557.USD","LU2488822045.USD","LU2328871848.SGD","BK0196","LU2097828714.EUR","LU1064131003.USD","LU1146622755.USD","LU2097828474.EUR","LU1064130708.USD","LU2097828805.USD","LU1580142542.USD","LU0359201885.HKD","LU2580892789.USD","BK0188","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626290241","title":"Hengrui Pharma schedules board meeting to review and release first-quarter results","url":"https://stock-news.laohu8.com/highlight/detail?id=2626290241","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626290241?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:31","pubTimestamp":1775723512,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals scheduled board meeting for April 22, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL7C37W8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1997244956.HKD","BK0239","LU2097828474.EUR","LU1655091616.SGD","LU1064130708.USD","600276","LU2580892862.HKD","LU2495084118.USD","LU1580142542.USD","LU2097828714.EUR","LU1969619763.USD","LU2097828805.USD","LU2328871848.SGD","LU0405327148.USD","BK0028","LU2097828557.USD","BK0196","LU1146622755.USD","LU1328615791.USD","LU1255011170.USD","BK0188","LU1064131003.USD","BK0060","LU2488822045.USD","LU2148510915.USD","LU1781817850.SGD","LU2097828631.EUR","LU1820825898.SGD","LU1997245177.USD","LU1997245094.SGD","BK0012","LU0405327494.USD","LU2580892789.USD","BK0183","LU2289578879.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133261785","title":"HENGRUI PHARMA Repurchases 64,800 A-Shares for 3.62 Million Yuan on April 7","url":"https://stock-news.laohu8.com/highlight/detail?id=1133261785","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133261785?lang=en_us&edition=fundamental","pubTime":"2026-04-08 06:36","pubTimestamp":1775601374,"startTime":"0","endTime":"0","summary":"HENGRUI PHARMA (01276) announced that on April 7, 2026, the company repurchased 64,800 A-shares at a total cost of 3.62 million yuan.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359201885.HKD","LU0359202008.SGD","399300","600276","LU1146622755.USD","LU2097828557.USD","BK1191","LU2097828805.USD","LU2289578879.USD","LU1580142542.USD","LU1328615791.USD","LU1255011170.USD","BK0196","BK0028","LU1064130708.USD","LU1023057109.AUD","BK0183","159982","LU1969619763.USD","LU1820825898.SGD","LU0405327148.USD","LU2148510915.USD","LU1781817850.SGD","BK0012","LU2580892789.USD","LU2097828714.EUR","LU2328871848.SGD","LU2580892862.HKD","LU1997244956.HKD","LU2097828474.EUR","01276","LU2495084118.USD","LU0405327494.USD","BK0060","LU2097828631.EUR","LU2543165471.USD","LU1997245094.SGD","BK0188","LU0359201612.USD","LU1655091616.SGD","LU1997245177.USD","LU1064131003.USD","BK0239","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625961734","title":"Jiangsu Hengrui files HKEX next-day return disclosing RMB 55.89/share buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=2625961734","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625961734?lang=en_us&edition=fundamental","pubTime":"2026-04-08 06:24","pubTimestamp":1775600693,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui filed next-day disclosure return reporting repurchase of 64,800 A shares on April 7.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL6xJ4jS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","LU1146622755.USD","LU2328871848.SGD","LU1064130708.USD","LU2580892789.USD","BK0012","LU2289578879.USD","LU1997245177.USD","LU2097828474.EUR","LU0405327494.USD","LU2097828805.USD","LU1328615791.USD","LU1064131003.USD","LU0405327148.USD","LU1781817850.SGD","BK0028","LU1997244956.HKD","BK0183","BK0060","LU2488822045.USD","LU1655091616.SGD","LU1820825898.SGD","LU1580142542.USD","LU2495084118.USD","BK0239","LU2580892862.HKD","LU1969619763.USD","LU1255011170.USD","600276","BK0188","LU2097828631.EUR","LU2148510915.USD","LU1997245094.SGD","LU2097828714.EUR","LU2097828557.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120500060","title":"Morgan Stanley Assigns \"Overweight\" Rating to Hengrui Pharma with HK$92 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1120500060","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120500060?lang=en_us&edition=fundamental","pubTime":"2026-04-01 14:04","pubTimestamp":1775023458,"startTime":"0","endTime":"0","summary":"Morgan Stanley has issued a research report assigning HENGRUI PHARMA (01276) an \"Overweight\" rating with a target price of HK$92. The report indicates that Hengrui Pharma is entering a new era of...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600276","LU1255011170.USD","BK0239","LU1580142542.USD","LU0359201885.HKD","BK0188","LU1655091616.SGD","LU0405327494.USD","LU2580892789.USD","LU2148510915.USD","LU2289578879.USD","LU2097828557.USD","LU2097828631.EUR","BK0012","BK0183","LU1969619763.USD","LU0405327148.USD","LU1064130708.USD","LU0359201612.USD","LU2488822045.USD","LU2328871848.SGD","LU2097828474.EUR","BK1191","BK0060","BK0196","LU0359202008.SGD","LU1997244956.HKD","LU1997245177.USD","LU1781817850.SGD","LU2097828714.EUR","01276","EWH","LU2097828805.USD","LU2495084118.USD","LU1064131003.USD","LU2543165471.USD","LU1328615791.USD","LU1023057109.AUD","LU1820825898.SGD","LU1146622755.USD","LU2580892862.HKD","BK0028","LU1997245094.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623534519","title":"BRIEF-Hengrui Pharma And Braveheart Bio Announce Positive Phase 2 Results With Hrs/BHB-1893 In Obstructive Hypertrophic Cardiomyopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2623534519","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623534519?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:44","pubTimestamp":1774878274,"startTime":"0","endTime":"0","summary":"BRIEF-Hengrui Pharma And Braveheart Bio Announce Positive Phase 2 Results With Hrs/BHB-1893 In Obstructive Hypertrophic CardiomyopathyMarch 30 (Reuters) - Jiangsu Hengrui Pharmaceuticals Co Ltd 600276","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nFWN40I0OW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK0012","BK0239","LU2097828714.EUR","LU1580142542.USD","BK0196","01276","BK0183","LU2580892789.USD","LU1997245177.USD","LU0405327148.USD","LU2543165471.USD","LU0359201885.HKD","LU1655091616.SGD","LU2148510915.USD","LU1820825898.SGD","LU2328871848.SGD","BK0028","LU1969619763.USD","BK0060","BK0188","LU1023057109.AUD","LU2097828805.USD","LU1997245094.SGD","LU2495084118.USD","LU1255011170.USD","LU1064130708.USD","LU2097828557.USD","LU0359201612.USD","BK1191","LU0405327494.USD","LU2289578879.USD","600276","LU0359202008.SGD","LU2097828474.EUR","LU1781817850.SGD","LU2580892862.HKD","LU1146622755.USD","LU1997244956.HKD","LU1328615791.USD","LU1064131003.USD","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623345800","title":"Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results With Hrs/Bhb-1893 in Obstructive Hypertrophic Cardiomyopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2623345800","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623345800?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:37","pubTimestamp":1774877836,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nFWN40I0OW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","BK0188","600276","LU1969619763.USD","LU1064130708.USD","LU0405327494.USD","LU1580142542.USD","LU2488822045.USD","LU1328615791.USD","LU1997244956.HKD","LU2580892862.HKD","BK0196","LU2097828805.USD","LU2580892789.USD","LU2097828557.USD","LU1064131003.USD","BK0183","LU1655091616.SGD","LU0359201612.USD","LU1023057109.AUD","LU1820825898.SGD","LU0405327148.USD","BK0012","LU2097828474.EUR","LU1997245177.USD","BK0028","LU2328871848.SGD","LU1997245094.SGD","LU2097828714.EUR","LU2289578879.USD","LU2495084118.USD","LU2097828631.EUR","01276","LU0359201885.HKD","LU2543165471.USD","LU0359202008.SGD","LU1255011170.USD","BK1191","LU2148510915.USD","BK0060","LU1781817850.SGD","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114111611","title":"New Appointments for Li Yanhong and Sun Piaoyang","url":"https://stock-news.laohu8.com/highlight/detail?id=1114111611","media":"Deep News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114111611?lang=en_us&edition=fundamental","pubTime":"2026-03-27 14:51","pubTimestamp":1774594315,"startTime":"0","endTime":"0","summary":"On March 27, news emerged that the Hong Kong Special Administrative Region (SAR) government has announced the appointment of four new members to the Chief Executive's Advisory Group. Their terms will...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2039709279.SGD","IE00B0JY6N72.USD","09888","LU0307460666.USD","LU0823426308.USD","LU2097828805.USD","LU1781817850.SGD","LU0173614495.USD","LU2328871848.SGD","LU1064130708.USD","BK0183","LU0588546209.SGD","LU2476274308.USD","LU0823426480.USD","LU1481107354.HKD","LU2580892789.USD","BK0188","BK0028","LU0417516902.SGD","BK0060","LU0640798160.USD","BK1609","BK1587","LU0821914370.USD","BK1095","LU0630378692.HKD","LU0072462343.USD","BK4526","LU1969619763.USD","IE0034224299.USD","LU1997245177.USD","LU0856984785.SGD","600276","BK4614","LU0405327148.USD","LU1997245094.SGD","LU1655091616.SGD","BK4588","LU0163747925.USD","SG9999002463.SGD","LU0229945570.USD","LU0359202008.SGD","SG9999002828.SGD","HK0000306685.HKD","BK4548","BK4535","LU2097828474.EUR","LU0831093199.SGD","BK1615","BK4587","BK0196","LU0348825331.USD","LU1146622755.USD","BK4602","LU0164880469.USD","LU0531971595.HKD","HK0000320223.HKD","LU0149721374.USD","LU2097828557.USD","LU1328615791.USD","LU1580142542.USD","BK4504","01276","LU1255011170.USD","KBDU","LU1820825898.SGD","LU2289578879.USD","LU2097828631.EUR","LU2488822045.USD","BK1588","LU0320764599.SGD","LU0871576103.HKD","LU0762542818.HKD","LU0051755006.USD","BK0239","LU0244354667.USD","LU1048596156.SGD","HK0000320264.USD","BK4077","LU1115378108.SGD","BK4579","LU2097828714.EUR","LU0762541174.USD","BK4585","LU1048588211.SGD","LU1064131003.USD","LU0405327494.USD","LU0543330566.HKD","BK0012","89888","LU1188198961.HKD","BIDU","LU0197773160.USD","LU0630378429.USD","LU0315179316.USD","LU1997244956.HKD","LU0164865239.USD","LU0287142896.SGD","LU2148510915.USD","LU0039217434.USD","LU0197773673.USD","LU0417516738.SGD","LU0463099449.HKD","BK4574","LU0052750758.USD","LU0228367735.SGD","LU0043850808.USD","LU0359201612.USD","LU0348735423.USD","SG9999014674.SGD","LU2580892862.HKD","BK1575","BIDG","LU1831875114.USD","BK4514","LU0456827905.SGD","LU0819121731.USD","BK4552","LU0762540952.USD","HK0000306701.USD","LU0708995583.HKD","LU1023057109.AUD","BK4543","BK4531","LU0326950275.SGD","LU2495084118.USD","LU2778985437.USD","BK4612"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1102992106","title":"SIMCERE PHARMA Shares Surge Nearly 8% in Morning Session Following Appointment of Former HENGRUI PHARMA Chairman as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=1102992106","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102992106?lang=en_us&edition=fundamental","pubTime":"2026-03-27 12:04","pubTimestamp":1774584261,"startTime":"0","endTime":"0","summary":"SIMCERE PHARMA (02096) saw its shares rise nearly 8% before the midday break. At the time of writing, the stock was up 7.87%, trading at HK$12.06, with a turnover of HK$45.592 million. On March 25,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064130708.USD","LU0405327494.USD","LU0405327148.USD","BK0028","LU2289578879.USD","LU1781817850.SGD","LU1023057109.AUD","LU1064131003.USD","01276","BK0196","LU2328871848.SGD","BK1191","LU1997245094.SGD","BK1583","02096","LU2097828474.EUR","BK0012","LU0359202008.SGD","LU2097828714.EUR","LU1328615791.USD","LU2097828805.USD","LU1255011170.USD","LU2495084118.USD","BK0188","LU2148510915.USD","LU0359201885.HKD","LU1969619763.USD","LU1997245177.USD","BK0183","LU2488822045.USD","VXUS","LU1820825898.SGD","LU0359201612.USD","BK0239","600276","LU1997244956.HKD","LU2580892789.USD","LU2580892862.HKD","LU1146622755.USD","LU1655091616.SGD","LU1580142542.USD","BK4588","BK0060","BK4585","LU2097828557.USD","LU2097828631.EUR","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622858533","title":"Jiangsu Hengrui gains China clinical trial clearance for HRS9531 injection; R&D spending grows to CNY 632 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622858533","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622858533?lang=en_us&edition=fundamental","pubTime":"2026-03-26 17:13","pubTimestamp":1774516410,"startTime":"0","endTime":"0","summary":"Hengrui said its subsidiary Fujian Shengdi received regulatory clearance in China to begin clinical trials of HRS9531, targeting risk reduction of major cardiovascular events in patients with atherosclerotic cardiovascular disease.The company stated there are no approved comparable drugs globally for this indication, positioning the program in a less crowded competitive landscape.Hengrui reported cumulative R&D spending for the HRS9531 program of about CNY 631.5 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 26, 2026, and is solely respons","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDLbr87fh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131003.USD","LU2097828714.EUR","LU1255011170.USD","LU1969619763.USD","LU2495084118.USD","LU1997245177.USD","BK0239","LU0405327494.USD","BK0196","LU1064130708.USD","LU2097828631.EUR","BK0012","LU1820825898.SGD","LU1328615791.USD","LU0405327148.USD","LU1997244956.HKD","LU2488822045.USD","LU2580892789.USD","BK0028","LU2580892862.HKD","LU1580142542.USD","LU2097828557.USD","BK0060","LU1997245094.SGD","LU2097828474.EUR","BK0188","LU1781817850.SGD","LU2289578879.USD","LU2328871848.SGD","LU2097828805.USD","LU1146622755.USD","BK0183","LU1655091616.SGD","LU2148510915.USD","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131023723","title":"Hengrui Pharma's HRS9531 Injection Receives Clinical Trial Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1131023723","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131023723?lang=en_us&edition=fundamental","pubTime":"2026-03-26 17:01","pubTimestamp":1774515707,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SH) announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has recently received a drug clinical trial approval notice for HRS9531...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1997245177.USD","BK0188","LU1328615791.USD","LU1064130708.USD","LU2097828805.USD","LU1969619763.USD","LU2289578879.USD","LU2543165471.USD","LU2148510915.USD","LU1023057109.AUD","LU2495084118.USD","01276","LU0359201885.HKD","LU2097828474.EUR","LU1781817850.SGD","LU2097828557.USD","BK0196","LU1997244956.HKD","LU2097828714.EUR","BK0060","LU0359202008.SGD","LU1064131003.USD","LU1146622755.USD","600276","LU0405327148.USD","LU1255011170.USD","LU1997245094.SGD","LU2097828631.EUR","BK1191","LU2580892862.HKD","LU0359201612.USD","LU0405327494.USD","BK0183","LU1580142542.USD","LU2488822045.USD","BK0012","BK0028","BK0239","LU2580892789.USD","LU1820825898.SGD","LU1655091616.SGD","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622881842","title":"Jiangsu Hengrui Pharmaceuticals' Profit, Revenue Climb in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2622881842","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622881842?lang=en_us&edition=fundamental","pubTime":"2026-03-26 09:24","pubTimestamp":1774488267,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals'  profit attributable to owners rose to 7.71 billion yuan for 2025, from 6.34 billion yuan a year earlier, according to a Thursday Hong Kong bourse filing.Earnings per share came in at 1.18 yuan, compared with 1.00 yuan a year earlier.Analysts at Visible Alpha expected EPS of 1.26 yuan.Revenue increased to 31.6 billion yuan from 28 billion yuan in 2024.Analysts at Visible Alpha expected revenue of 32.4 billion yuan.The board proposed a final dividend of 0.20 yuan per share, subject to shareholder approval, with payment expected within two months after the annual general meeting.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1255011170.USD","LU1969619763.USD","LU2148510915.USD","LU1064131003.USD","LU2328871848.SGD","BK0012","LU1781817850.SGD","01276","LU1997245177.USD","BK1191","LU2097828714.EUR","BK0188","BK0196","LU1023057109.AUD","LU0359201612.USD","LU2580892789.USD","BK0028","LU2289578879.USD","LU0359201885.HKD","LU2543165471.USD","LU1064130708.USD","LU1146622755.USD","LU0405327148.USD","LU2097828474.EUR","LU1655091616.SGD","LU2495084118.USD","LU0405327494.USD","LU2097828805.USD","LU1820825898.SGD","BK0060","LU2097828557.USD","LU2580892862.HKD","LU1997244956.HKD","BK0239","LU1328615791.USD","LU1580142542.USD","LU2097828631.EUR","LU0359202008.SGD","LU1997245094.SGD","BK0183","LU2488822045.USD","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622288675","title":"Hengrui Pharma Announces Strong 2025 Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622288675","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622288675?lang=en_us&edition=fundamental","pubTime":"2026-03-26 08:52","pubTimestamp":1774486357,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUA9XVHXG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1655091616.SGD","BK0012","BK0183","LU2580892862.HKD","LU2488822045.USD","LU2328871848.SGD","LU2580892789.USD","LU1146622755.USD","BK0060","LU1997245094.SGD","LU2289578879.USD","LU2097828631.EUR","LU1997245177.USD","LU0405327494.USD","LU1997244956.HKD","BK0239","LU2097828474.EUR","LU2495084118.USD","LU1781817850.SGD","LU1064130708.USD","LU1328615791.USD","BK0196","LU1064131003.USD","BK0028","LU1255011170.USD","BK0188","LU0405327148.USD","LU1580142542.USD","LU2097828557.USD","600276","LU2148510915.USD","LU1820825898.SGD","LU2097828805.USD","LU1969619763.USD","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622888582","title":"Jiangsu Hengrui Medicine FY2025 final dividend is proposed at RMB 2 per 10 shares; shareholder approval is set for April 16, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2622888582","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622888582?lang=en_us&edition=fundamental","pubTime":"2026-03-26 06:33","pubTimestamp":1774477983,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine FY2025 final dividend is proposed at RMB 2 per 10 shares; shareholder approval is set for April 16, 2026. Hengrui proposed a final ordinary dividend of RMB 2 per 10 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 25, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL9JvxsY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","LU0405327148.USD","LU1064130708.USD","LU1820825898.SGD","LU2148510915.USD","LU2488822045.USD","BK0183","BK0012","LU2580892789.USD","LU1997245094.SGD","LU1328615791.USD","LU1781817850.SGD","LU1580142542.USD","LU2097828557.USD","LU1655091616.SGD","LU2495084118.USD","600276","LU1997244956.HKD","LU2097828805.USD","LU2097828474.EUR","BK0196","LU1969619763.USD","LU2328871848.SGD","BK0239","LU2289578879.USD","LU2580892862.HKD","LU0405327494.USD","LU1997245177.USD","LU2097828631.EUR","LU1064131003.USD","LU1255011170.USD","BK0188","LU2097828714.EUR","BK0028","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622883778","title":"Jiangsu Hengrui Medicine FY2025 publishes ESG report; MSCI ESG rating climbs to AA","url":"https://stock-news.laohu8.com/highlight/detail?id=2622883778","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622883778?lang=en_us&edition=fundamental","pubTime":"2026-03-26 06:32","pubTimestamp":1774477924,"startTime":"0","endTime":"0","summary":"Hengrui released its fifth ESG report, covering environmental protection, social responsibilities, and corporate governance across the company and subsidiaries included in its financial statements.Environmental disclosures include ISO 14001 certification for 7 core manufacturing entities, representing 70% coverage.Energy conservation measures reported carbon emissions reductions of more than 7,434.75 tons and photovoltaic projects generated 1.14 million kWh.Governance disclosures include 3 shareholders’ meetings and 10 board meetings, and anti-corruption training coverage of 100% of employees with 238,070 training hours.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDLbDJwbN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828557.USD","LU2488822045.USD","LU1064130708.USD","LU2097828805.USD","LU2580892862.HKD","LU1997245094.SGD","LU2148510915.USD","LU2289578879.USD","LU2580892789.USD","LU2495084118.USD","LU1969619763.USD","BK0188","LU1997244956.HKD","LU1781817850.SGD","BK0183","LU0405327148.USD","LU1997245177.USD","BK0012","LU1328615791.USD","LU2097828631.EUR","BK0060","LU2328871848.SGD","LU1146622755.USD","LU1820825898.SGD","LU1580142542.USD","LU2097828714.EUR","LU1255011170.USD","LU0405327494.USD","BK0196","LU1064131003.USD","BK0028","LU1655091616.SGD","600276","LU2097828474.EUR","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622107090","title":"BRIEF-Jiangsu Hengrui Pharmaceuticals Entered Into Capital Increase Agreement With Hengrui Group, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2622107090","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622107090?lang=en_us&edition=fundamental","pubTime":"2026-03-25 23:29","pubTimestamp":1774452572,"startTime":"0","endTime":"0","summary":"BRIEF-Jiangsu Hengrui Pharmaceuticals Entered Into Capital Increase Agreement With Hengrui Group, OthersMarch 25  - Jiangsu Hengrui Pharmaceuticals 600276.SS:ENTERED INTO CAPITAL INCREASE AGREEMENT WITH HENGRUI GROUP, OTHERSCO, OTHERS TO CONTRIBUTE IN AGGREGATE RMB750.0 MILLIONFurther company coverage: 600276.SS ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40D0Y2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0028","LU1146622755.USD","LU1969619763.USD","BK0239","600276","LU2097828714.EUR","LU1997245177.USD","LU1580142542.USD","BK0183","LU0359201612.USD","LU1781817850.SGD","LU1820825898.SGD","LU0405327494.USD","LU2097828557.USD","LU0359202008.SGD","LU2328871848.SGD","BK0060","LU1064131003.USD","LU1997244956.HKD","LU2148510915.USD","LU2580892862.HKD","LU1255011170.USD","LU0405327148.USD","LU2289578879.USD","BK0196","LU1023057109.AUD","01276","BK0012","LU1328615791.USD","LU0359201885.HKD","LU2580892789.USD","LU2097828805.USD","BK1191","LU1064130708.USD","LU1997245094.SGD","LU1655091616.SGD","LU2097828474.EUR","LU2488822045.USD","LU2097828631.EUR","LU2495084118.USD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193333530","title":"HENGRUI PHARMA to Inject 285 Million Yuan into Shanghai Ruihongdi","url":"https://stock-news.laohu8.com/highlight/detail?id=1193333530","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193333530?lang=en_us&edition=fundamental","pubTime":"2026-03-25 23:28","pubTimestamp":1774452481,"startTime":"0","endTime":"0","summary":"HENGRUI PHARMA (01276) has announced the signing of a capital increase agreement on March 25, 2026, with Hengrui Group, Shengdi Biopharmaceutical Fund, Shenzhen Yingtai, and Shanghai Ruihongdi. The...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359202008.SGD","BK0028","BK0183","LU2543165471.USD","LU0405327148.USD","LU2488822045.USD","LU2097828805.USD","LU2495084118.USD","LU2580892862.HKD","LU1781817850.SGD","BK0012","600276","LU1820825898.SGD","LU2580892789.USD","LU2097828714.EUR","LU1580142542.USD","LU1146622755.USD","BK0188","LU1997245094.SGD","BK1191","LU1997244956.HKD","LU1328615791.USD","LU0405327494.USD","LU1969619763.USD","LU1997245177.USD","LU0359201612.USD","LU1023057109.AUD","LU2148510915.USD","BK0060","LU2097828631.EUR","01276","LU1064131003.USD","BK0196","LU1655091616.SGD","LU2328871848.SGD","LU2289578879.USD","LU1255011170.USD","LU2097828557.USD","LU2097828474.EUR","LU0359201885.HKD","BK0239","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160973805","title":"SIMCERE PHARMA Announces Dr. Zhou Yunshu as New CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=1160973805","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160973805?lang=en_us&edition=fundamental","pubTime":"2026-03-25 23:06","pubTimestamp":1774451178,"startTime":"0","endTime":"0","summary":"SIMCERE PHARMA (02096) has announced the appointment of Dr. Zhou Yunshu as Chief Executive Officer, effective March 25, 2026. In this role, Dr. Zhou, as a senior management member, will be...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","LU2097828714.EUR","BK0028","LU1064131003.USD","BK0196","600276","BK0188","LU2488822045.USD","LU1255011170.USD","LU2097828557.USD","LU1820825898.SGD","LU1328615791.USD","LU2097828631.EUR","LU2097828474.EUR","LU2328871848.SGD","LU2097828805.USD","LU1580142542.USD","02096","LU1997245177.USD","LU1064130708.USD","LU2495084118.USD","BK1583","LU1146622755.USD","LU1997244956.HKD","LU2580892789.USD","BK0239","BK0060","LU2148510915.USD","LU1969619763.USD","LU0405327148.USD","LU1655091616.SGD","LU2289578879.USD","LU2580892862.HKD","BK0183","BK1191","LU1781817850.SGD","LU0405327494.USD","LU1997245094.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622077678","title":"Jiangsu Hengrui Pharmaceuticals - Entered Capital Increase Agreement With Hengrui Group, Shengdi Biomedical Fund, and Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2622077678","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622077678?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:58","pubTimestamp":1774450726,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40D10P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0196","LU1146622755.USD","LU2328871848.SGD","LU1064130708.USD","LU2580892789.USD","BK0012","LU2289578879.USD","LU1997245177.USD","LU2097828474.EUR","LU0405327494.USD","LU2097828805.USD","LU1328615791.USD","LU1064131003.USD","LU0405327148.USD","LU1781817850.SGD","BK0028","LU1997244956.HKD","BK0183","BK0060","LU0359201885.HKD","LU2488822045.USD","LU1655091616.SGD","LU1023057109.AUD","LU1580142542.USD","LU1820825898.SGD","LU2495084118.USD","BK0239","LU2580892862.HKD","LU0359202008.SGD","BK1191","LU1255011170.USD","LU1969619763.USD","01276","600276","BK0188","LU2543165471.USD","LU0359201612.USD","LU2097828631.EUR","LU2148510915.USD","LU1997245094.SGD","LU2097828714.EUR","LU2097828557.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622077983","title":"Jiangsu Hengrui Pharmaceuticals -  Co, Others to Contribute in Aggregate RMB750.0 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2622077983","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622077983?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:58","pubTimestamp":1774450714,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40D0Y2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2543165471.USD","BK0239","LU1997245094.SGD","LU1064131003.USD","LU0405327148.USD","BK0183","LU0359201612.USD","BK0028","LU1969619763.USD","LU1997244956.HKD","LU1064130708.USD","BK0012","LU1146622755.USD","LU2097828474.EUR","LU2097828714.EUR","LU1255011170.USD","LU2289578879.USD","LU1781817850.SGD","LU0405327494.USD","LU1655091616.SGD","LU1580142542.USD","LU2328871848.SGD","LU1997245177.USD","LU2148510915.USD","LU0359202008.SGD","LU2495084118.USD","LU2097828631.EUR","LU2097828557.USD","LU2488822045.USD","LU2580892789.USD","BK1191","LU1328615791.USD","BK0060","LU1023057109.AUD","LU0359201885.HKD","LU1820825898.SGD","01276","BK0188","600276","BK0196","LU2580892862.HKD","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","stockEarnings":[{"period":"1week","weight":-0.0049},{"period":"1month","weight":0.0457},{"period":"3month","weight":-0.0967},{"period":"6month","weight":-0.1576},{"period":"1year","weight":0.1839},{"period":"ytd","weight":-0.0356}],"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","perCapita":"14186股","boardName":"医药制造业","registeredCapital":"663719万元","compareEarnings":[{"period":"1week","weight":0.0118},{"period":"1month","weight":-0.0248},{"period":"3month","weight":-0.0215},{"period":"6month","weight":0.0251},{"period":"1year","weight":0.27},{"period":"ytd","weight":0.0066}],"survey":"　　江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。","serverTime":1775732069138,"listedPrice":11.98,"stockholders":"449644人(较上一季度增加12.84%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.,600276,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票老虎,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票老虎国际,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.行情,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票行情,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股价,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股市,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票价格,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票交易,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票购买,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}